

Special Issue

PSMA PET/CT in Prostate Cancer

Message from the Guest Editor

The introduction of PSMA PET/CT into clinical use has had a major impact on our management of prostate cancer. Its initial utilization was in the identification of disease in biochemical recurrence and, shortly after that, it became recognized as a superior tool in primary staging at diagnosis. The potential roles of PSMA PET/CT continue to expand and there is growing data to demonstrate its utility in the assessment of local disease. As such, there are emerging data that demonstrate its utility in diagnosis, active surveillance, and as a biomarker. This novel imaging has also paved the way for a therapeutic option and the exponential growth of interest in theranostics. We are pleased to invite you to contribute manuscripts that provide emerging or mature data on how PSMA PET/CT has influenced prostate cancer management in your institution or systematically evaluate the research experience in specific applications of PSMA PET/CT. The aim of this Special Issue is to create a collection of papers that define the use of this novel form of imaging in urological clinical practice. I look forward to receiving your contributions.

Guest Editor

Dr. Henry Hyunshik Woo

Department of Urology, Chris O'Brien Lifehouse, Sydney, NSW 2050, Australia

Deadline for manuscript submissions

closed (20 November 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/188690

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)